Standard Life Aberdeen plc trimmed its position in HCP, Inc. (NYSE:HCP) by 21.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 241,269 shares of the real estate investment trust’s stock after selling 66,674 shares during the period. Standard Life Aberdeen plc owned 0.05% of HCP worth $6,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Piedmont Investment Advisors LLC acquired a new position in shares of HCP in the 2nd quarter valued at $142,000. Archford Capital Strategies LLC acquired a new position in shares of HCP in the 1st quarter valued at $167,000. Reliance Trust Co. of Delaware acquired a new position in shares of HCP in the 2nd quarter valued at $211,000. Atlas Brown Inc. acquired a new position in shares of HCP in the 2nd quarter valued at $226,000. Finally, Advisor Partners LLC acquired a new position in shares of HCP in the 1st quarter valued at $228,000. 88.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of HCP opened at $26.54 on Wednesday. The stock has a market cap of $12.70 billion, a price-to-earnings ratio of 14.15, a P/E/G ratio of 6.71 and a beta of 0.27. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.51 and a current ratio of 0.51. HCP, Inc. has a fifty-two week low of $21.48 and a fifty-two week high of $30.59.
HCP (NYSE:HCP) last announced its quarterly earnings results on Thursday, August 2nd. The real estate investment trust reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.27). The company had revenue of $469.60 million for the quarter, compared to analyst estimates of $463.94 million. HCP had a return on equity of 1.12% and a net margin of 3.39%. HCP’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.48 earnings per share. analysts expect that HCP, Inc. will post 1.82 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, August 21st. Shareholders of record on Wednesday, August 8th were given a dividend of $0.37 per share. This represents a $1.48 annualized dividend and a yield of 5.58%. The ex-dividend date of this dividend was Friday, August 3rd. HCP’s dividend payout ratio is currently 75.90%.
Several research firms recently issued reports on HCP. ValuEngine raised HCP from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 26th. Raymond James reissued a “market perform” rating on shares of HCP in a research report on Friday, June 1st. Evercore ISI downgraded HCP from an “in-line” rating to an “underperform” rating in a research report on Friday, June 1st. Zacks Investment Research raised HCP from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. Finally, Cantor Fitzgerald began coverage on HCP in a research report on Tuesday, August 7th. They set a “neutral” rating and a $28.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $26.25.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Featured Article: Book Value Per Share – BVPS
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.